The BfArM issues information that the variation worksharing procedure regarding progressive multifocal leukoencephalopathy in connection with the use of medicinal products containing dimethyl fumarate has been concluded.

To the risk information - full text (available in German only)

For the complete recommendations please click on the following link to the homepage of the European Medicines Agency (EMA):